CR20220626A - Compuestos para el tratamiento de enfermedades y trastornos asociados a braf - Google Patents
Compuestos para el tratamiento de enfermedades y trastornos asociados a brafInfo
- Publication number
- CR20220626A CR20220626A CR20220626A CR20220626A CR20220626A CR 20220626 A CR20220626 A CR 20220626A CR 20220626 A CR20220626 A CR 20220626A CR 20220626 A CR20220626 A CR 20220626A CR 20220626 A CR20220626 A CR 20220626A
- Authority
- CR
- Costa Rica
- Prior art keywords
- braf
- disorders
- treatment
- dihydroquinazolinon
- oxo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Se proporciona en la presente un compuesto de la Fórmula I, o una sal aceptable desde el punto de vista farmacéutico de este, en donde R1, R2, R3, R4, R5, R6, R7 y L son como se definen en la presente, para el tratamiento de enfermedades y trastornos asociados a BRAF, incluso tumores asociados a BRAF.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063036522P | 2020-06-09 | 2020-06-09 | |
US202063116204P | 2020-11-20 | 2020-11-20 | |
US202163175655P | 2021-04-16 | 2021-04-16 | |
PCT/IB2021/054919 WO2021250521A1 (en) | 2020-06-09 | 2021-06-04 | 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20220626A true CR20220626A (es) | 2023-01-23 |
Family
ID=76355554
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20220626A CR20220626A (es) | 2020-06-09 | 2021-06-04 | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf |
Country Status (19)
Country | Link |
---|---|
US (1) | US20220288074A1 (es) |
EP (1) | EP4161907A1 (es) |
JP (2) | JP7312335B2 (es) |
KR (1) | KR20230019944A (es) |
CN (1) | CN116096710A (es) |
AU (1) | AU2021289163B2 (es) |
BR (1) | BR112022024597A2 (es) |
CA (1) | CA3186343A1 (es) |
CL (1) | CL2022003326A1 (es) |
CO (1) | CO2022017876A2 (es) |
CR (1) | CR20220626A (es) |
DO (1) | DOP2022000282A (es) |
EC (1) | ECSP22093029A (es) |
IL (1) | IL298300A (es) |
MX (1) | MX2022015703A (es) |
PE (1) | PE20231651A1 (es) |
TW (1) | TWI837478B (es) |
UY (1) | UY39261A (es) |
WO (1) | WO2021250521A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ.ベー. | 置換ピラゾロピラジン及びglun2b受容体調節因子としてのそれらの使用 |
PE20221027A1 (es) * | 2019-12-10 | 2022-06-16 | Hoffmann La Roche | Nuevos inhibidores de braf como rompedores de la paradoja |
TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶-1,6(2h,7h)-二酮 |
WO2023105371A1 (en) * | 2021-12-08 | 2023-06-15 | Array Biopharma Inc. | Crystalline form of n-(2-chloro-3-((5-chloro-3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)-4-fluorophenyl)-3-fluoroazetidine-1-sulfonamide |
US20230293465A1 (en) * | 2022-03-17 | 2023-09-21 | St. Jude Children’S Research Hospital | Treatment of low-grade glioma with mirdametinib |
WO2023183470A1 (en) * | 2022-03-24 | 2023-09-28 | Vibliome Therapeutics, Llc | Modulators of protein kinases |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
WO2024126660A1 (en) * | 2022-12-15 | 2024-06-20 | F. Hoffmann-La Roche Ag | Combination therapy for cancer treatment |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3000810B1 (en) | 2002-03-13 | 2017-07-19 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivative as mek inhibitor |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7598383B2 (en) | 2003-11-19 | 2009-10-06 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
CN102942522A (zh) | 2005-05-18 | 2013-02-27 | 阵列生物制药公司 | Mek的杂环抑制剂及其使用方法 |
WO2012118492A1 (en) * | 2011-03-01 | 2012-09-07 | Array Biopharma Inc. | Heterocyclic sulfonamides as raf inhibitors |
CN108779079A (zh) | 2016-01-06 | 2018-11-09 | 特里乌姆治疗公司 | 作为egfr抑制剂的新的氟化喹唑啉衍生物 |
US10898487B2 (en) | 2016-12-22 | 2021-01-26 | Boehringer Ingelheim International Gmbh | Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors |
WO2019071351A1 (en) | 2017-10-12 | 2019-04-18 | Trillium Therapeutics Inc. | NOVEL 4-ARYLOXYQUINAZOLINE FLUORIN DERIVATIVES AS EGFR INHIBITORS USEFUL FOR THE TREATMENT OF CANCERS |
WO2020055992A1 (en) | 2018-09-11 | 2020-03-19 | NetraDyne, Inc. | Inward/outward vehicle monitoring for remote reporting and in-cab warning enhancements |
TWI817018B (zh) | 2019-06-28 | 2023-10-01 | 美商艾瑞生藥股份有限公司 | 用於治療braf相關的疾病和失調症之化合物 |
-
2021
- 2021-06-04 JP JP2022575381A patent/JP7312335B2/ja active Active
- 2021-06-04 US US17/338,767 patent/US20220288074A1/en active Pending
- 2021-06-04 TW TW110120375A patent/TWI837478B/zh active
- 2021-06-04 IL IL298300A patent/IL298300A/en unknown
- 2021-06-04 WO PCT/IB2021/054919 patent/WO2021250521A1/en active Application Filing
- 2021-06-04 BR BR112022024597A patent/BR112022024597A2/pt active Search and Examination
- 2021-06-04 MX MX2022015703A patent/MX2022015703A/es unknown
- 2021-06-04 AU AU2021289163A patent/AU2021289163B2/en active Active
- 2021-06-04 CR CR20220626A patent/CR20220626A/es unknown
- 2021-06-04 EP EP21731307.1A patent/EP4161907A1/en active Pending
- 2021-06-04 CN CN202180056068.XA patent/CN116096710A/zh active Pending
- 2021-06-04 KR KR1020237000172A patent/KR20230019944A/ko unknown
- 2021-06-04 CA CA3186343A patent/CA3186343A1/en active Pending
- 2021-06-04 PE PE2022002894A patent/PE20231651A1/es unknown
- 2021-06-08 UY UY0001039261A patent/UY39261A/es unknown
-
2022
- 2022-11-25 CL CL2022003326A patent/CL2022003326A1/es unknown
- 2022-12-07 EC ECSENADI202293029A patent/ECSP22093029A/es unknown
- 2022-12-08 DO DO2022000282A patent/DOP2022000282A/es unknown
- 2022-12-09 CO CONC2022/0017876A patent/CO2022017876A2/es unknown
-
2023
- 2023-07-07 JP JP2023112365A patent/JP2023123854A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
PE20231651A1 (es) | 2023-10-17 |
MX2022015703A (es) | 2023-01-24 |
CO2022017876A2 (es) | 2022-12-20 |
DOP2022000282A (es) | 2023-03-31 |
BR112022024597A2 (pt) | 2022-12-27 |
WO2021250521A1 (en) | 2021-12-16 |
IL298300A (en) | 2023-01-01 |
ECSP22093029A (es) | 2023-02-28 |
CL2022003326A1 (es) | 2023-02-24 |
US20220288074A1 (en) | 2022-09-15 |
TWI837478B (zh) | 2024-04-01 |
UY39261A (es) | 2022-01-31 |
EP4161907A1 (en) | 2023-04-12 |
JP2023524910A (ja) | 2023-06-13 |
AU2021289163A1 (en) | 2022-12-22 |
AU2021289163B2 (en) | 2024-05-02 |
CA3186343A1 (en) | 2021-12-16 |
CN116096710A (zh) | 2023-05-09 |
JP2023123854A (ja) | 2023-09-05 |
KR20230019944A (ko) | 2023-02-09 |
TW202214577A (zh) | 2022-04-16 |
JP7312335B2 (ja) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20220626A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf | |
PH12019501350A1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
EP4356973A3 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
CR20210387A (es) | Inhibidores de kif18a | |
PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
EA201000016A1 (ru) | Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями | |
MX2018003351A (es) | Derivados de pirazolopirimidina como inhibidores de la btk para el tratramiento de cancer. | |
MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
MX2021010888A (es) | Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis. | |
CR20220207A (es) | Compuestos terapéuticos y métodos de uso | |
JOP20210164A1 (ar) | طرق وتركيبات علاج السرطان | |
PH12021550443A1 (en) | Pyridazinones and methods of use thereof | |
MX2023004942A (es) | Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades. | |
WO2020132658A3 (en) | Tubulysins and protein-tubulysin conjugates | |
JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
MX2023008589A (es) | Compuestos moduladores de gcn2 y usos de los mismos. | |
MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
MX2022003671A (es) | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. | |
EA202092540A1 (ru) | Комбинации для лечения рака | |
MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
JOP20200090A1 (ar) | عملية لتحضير بنزوثيوفين-2 يل بورونات |